Biotechnology Assets, S.A. (BME:BST)
Spain
· Delayed Price · Currency is EUR 0.3110
-0.0060 (-1.89%)
Jun 18, 2025, 5:18 PM CET
Biotechnology Assets Revenue
In the year 2024, Biotechnology Assets had annual revenue of 2.97M EUR, down -24.13%. Biotechnology Assets had revenue of 1.86M in the half year ending December 31, 2024, with 3.34% growth.
Revenue
2.97M
Revenue Growth
-24.13%
P/S Ratio
7.10
Revenue / Employee
87.21K
Employees
34
Market Cap
21.05M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.97M | -943.29K | -24.13% |
| Dec 31, 2023 | 3.91M | 950.58K | 32.14% |
| Dec 31, 2022 | 2.96M | -324.07K | -9.87% |
| Dec 31, 2021 | 3.28M | 390.31K | 13.50% |
| Dec 31, 2020 | 2.89M | -345.59K | -10.68% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Grifols | 7.37B |
| Laboratorios Farmaceuticos Rovi | 767.47M |
| Almirall | 1.03B |
| Pharma Mar | 175.75M |
| Faes Farma | 524.02M |
| Clínica Baviera | 279.53M |
| Laboratorio Reig Jofre | 340.41M |
| Oryzon Genomics | 7.36M |